Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06976372 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or Obesity
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
NCT06976372 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 120 participants.
The verdict
NCT06976372, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the pharmacokinetics (PK) of AMG 133 after multiple subcutaneous (SC) administrations in participants with overweight or obesity using various dose regimens.
Interventions
- DRUG AMG 133
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-08-20 |
| Est. Completion | 2024-12-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06976372
The ClinicalTrials.gov registry entry for NCT06976372 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMG 133 is the first listed.
NCT06976372 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06976372 about?
NCT06976372 is a clinical study titled "A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or Obesity". The primary objective of this study is to assess the pharmacokinetics (PK) of AMG 133 after multiple subcutaneous (SC) administrations in participants with overweight or obesity using various dose regimens.
What is the current status of trial NCT06976372?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2024-08-20. Estimated completion is 2024-12-27.
What interventions are being tested in trial NCT06976372?
The interventions under investigation include: AMG 133 (DRUG).
Who is sponsoring clinical trial NCT06976372?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.